Pegfilgrastim Bone Pain: New Strategy for Breast Cancer Patients

Delayed administration of pegfilgrastim, a medication used to prevent infection in breast cancer patients undergoing chemotherapy, may significantly reduce the debilitating bone pain often associated with its apply, according to a study published online March 24 in the Annals of Internal Medicine.

Pegfilgrastim is a myeloid growth factor that stimulates the production of white blood cells, helping to counteract myelosuppression – a common side effect of chemotherapy that weakens the immune system. Although effective in preventing infection, pegfilgrastim is known to cause significant bone pain in a substantial number of patients.

The novel research indicates that administering the drug 72 hours after chemotherapy, rather than the standard 24 or 48 hours, substantially lessens the incidence and severity of this bone pain. The study did not detail the methodology used to determine the reduction in pain, but the findings offer a simple adjustment to current practice that could improve patient comfort.

Myeloid growth factors, including filgrastim and pegfilgrastim, are considered essential components of treatment for many adjuvant chemotherapy regimens used in early-stage breast cancer, particularly those involving anthracyclines and taxanes. A 2006 study at Dana-Farber Cancer Institute evaluated the use of pegfilgrastim in supporting every-two-week adjuvant chemotherapy for early-stage breast cancer, administering it to 134 patients receiving dose-dense AC followed by paclitaxel.

A retrospective chart review conducted at a multistate health system, published in 2018, found that reduced doses of pegfilgrastim – often implemented to mitigate bone pain or leukocytosis – still resulted in a low incidence of neutropenia-associated events, including febrile neutropenia and grade 3/4 neutropenia. The review of 80 patients showed only one case of febrile neutropenia that did not require hospitalization or intravenous antibiotics, and minimal chemotherapy delays or dose reductions.

Researchers have also explored alternative administration schedules to minimize side effects. A study published in 2021 investigated the feasibility of administering pegfilgrastim on the same day as chemotherapy (cbqv) for primary and secondary prophylaxis of febrile neutropenia in breast cancer treatment, finding it to be a safe and effective option.

The findings regarding delayed administration of pegfilgrastim add another potential strategy for managing treatment-related side effects. Further research is needed to fully understand the optimal timing and dosage of pegfilgrastim to maximize its benefits while minimizing discomfort for patients.